Medlab Clinical Ltd (ASX: MDC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Medlab Clinical Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.07 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.28 million
Earnings per share -547.781
Dividend per share N/A
Year To Date Return N/A
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Medlab Clinical Ltd (ASX: MDC)
    Latest News

    Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
    Healthcare Shares

    Why is the Medlab (ASX:MDC) share price surging 8% today?

    The Medlab (ASX: MDC) share price is rising today after the European Patent Office announced its intention to grant Nanocelle…

    Read more »

    high share price
    Share Market News

    Here's why the Medlab (ASX:MDC) share price is rising today

    The Medlab Clinical Ltd (ASX: MDC) share price is treading upwards today after announcing an agreement Arrotex. Here's what you…

    Read more »

    a woman
    Share Gainers

    Why Clean TeQ, Medlab, Newcrest, & Ramelius are storming higher today

    Medlab Clinical Ltd (ASX:MDC) and Newcrest Mining Limited (ASX:NCM) shares are storming higher on Monday. Here's why...

    Read more »

    a woman
    Share Gainers

    Why this ASX cannabis share is shooting 15% higher today

    The Medlab Clinical Ltd (ASX:MDC) share price is shooting higher on Monday despite the market selloff. Here's why this cannabis…

    Read more »

    a woman
    Share Gainers

    Why THC Global and these ASX cannabis shares are rocketing higher today

    The THC Global Group Ltd (ASX:THC) share price and these cannabis shares are rocketing higher on Monday. Here's why...

    Read more »

    a woman
    52-Week Highs

    Why this ASX biotech is printing 52-week highs

    The Medlab Clinical Ltd (ASX: MDC) share price is rising after the company announced it has signed a Heads of Agreement…

    Read more »

    a woman
    Share Gainers

    This small-cap ASX biotech's share price is soaring today

    An operations update for the June quarter sees the Medlab Clinical Ltd (ASX: MDC) share price soar in Thursday trade.

    Read more »

    a woman
    Share Gainers

    Why Medlab, Metcash, SKY and Space Global, and WiseTech shares charged higher today

    The Metcash Limited (ASX:MTS) share price and the WiseTech Global Ltd (ASX:WTC) share price are two of four charging higher…

    Read more »

    a woman
    Share Market News

    These small cap ASX shares are on the rise today

    The Slater & Gordon Limited (ASX:SGH) share price is one of three in the small cap space climbing higher on…

    Read more »

    a woman
    ⏸️ Investing

    Is Medlab Clinical Ltd the best small cap healthcare buy on the ASX?

    brokers are circling biological research company Medlab Clinical Ltd (ASX: MDC) as a potential buy

    Read more »

    a woman
    ⏸️ Investing

    Why these pot stocks are moving higher

    Pot stocks continue to provide investors with strong returns…

    Read more »

    a woman
    ⏸️ Investing

    Why shares of Medlab Clinical Ltd have risen 37% in 2018

    Shares of Medlab Clinical Ltd (ASX:MDC) have had an excellent start to 2018 with the company's share price rising 37% to…

    Read more »

    MDC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Medlab Clinical Ltd

    Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael Kenneth Carter Non-Executive Director Mar 2023
    Mr Carter is experienced in structuring corporate transactions and has also worked in ongoing corporate advisory roles with numerous ASX listed entities over the last 18 years. Mr Carter has been employed as a stockbroker since 1999 and was previously a director of Indian Ocean Capital. He is currently an associate director of CPS Capital Group and Non-Executive Director of European Lithium Ltd.
    Mr Matthew John Hudson Non-Executive Director Mar 2023
    Mr Hudson has experience raising capital for projects based in Africa, Latin America, and Asia. He is a former Credit Suisse and Arthur Andersen advisor, who is now the Co Founder and Managing Director of Hudson Koch Energy. He is also the Founder and Managing Director of United Minerals which operated the historic Potosi Mine in Chihuahua, Mexico.
    Mr Sean Michael Hall Chief Executive OfficerManaging Director Apr 2014
    Dr Hall has over 20 years experience in the Australian Healthcare and food industries and early phase drug discovery in Australia and Asia. Sean is best known for building Australia's leading practitioner brand, BioCeuticals. Dr Hall is an active member of Medicines Australia, American Federation for Medical Research, American Academy of Anti-Ageing Medicine, Ausbiotech, a member of the Scientific Advisory Board for BITs Life Science China and a Board Member of the International Probiotics Association.
    Mr Kerem Kaya Chief Financial OfficerCompany Secretary May 2021
    -
    Kerem Kaya Chief Financial OfficerCompany Secretary
    -
    Ian Curtinsmith Chief Information Officer
    -
    Luis Vitetta Director of Medical Research
    -
    David Rutolo Director of Science
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Sean Michael Hall 386,838 16.94%
    Farjoy Pty Ltd 205,663 9.01%
    HSBC Custody Nominees (Australia) Limited 106,111 4.65%
    UBS Nominees Pty Ltd 85,316 3.74%
    Fit Investments Pty Ltd <Hallab Investment A/C> 75,563 3.31%
    BNP Paribas Nominees Pty Ltd 73,787 3.23%
    Realm Group Pty Ltd 70,000 3.07%
    Richard Albarran <Albarran Family No 2 A/C> 37,038 1.62%
    Rolay Pty Ltd 37,038 1.62%
    United Trolley Collections P/L 32,970 1.44%
    Mr Michael Jack Hall + Mrs Elizabeth Ann Jones <Hall Jones Super Fund A/C> 29,820 1.31%
    Citicorp Nominees Pty Limited 21,193 0.93%
    Villamagna Inc 20,000 0.88%
    Netwealth Investments Limited 18,839 0.83%
    Acron Holdings Pty Limited <Acron Super Fund A/C> 16,181 0.71%
    Assumo (Nominees) Pty Ltd <Assumo Super Fund A/C> 13,334 0.58%
    D J Fairfull Pty Ltd <Fairfull Super Fund A/C> 12,651 0.55%
    Miss Xiaodan Fu 11,902 0.52%
    Deni Freighters Super Fund Pty Ltd <Deniliquin Freighters Super Fund A/C> 10,001 0.44%
    Daniel P Moses (Nominees) Pty Ltd <Daniel Moses Family A/C> 10,000 0.44%

    Profile

    since

    Note